Cyclin-dependent kinase (CDK) 4/6 inhibitors may be a potential game changer in breast cancer therapy, with promising results from the MONALEESA-2 trial sub-analysis showing that ribociclib, in combination with letrozole, significantly improved progression-free survival (PFS) in Asian women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer.
Afatinib failed to demonstrate an overall survival (OS) benefit vs gefitinib in patients with non-small-cell lung cancer (NSCLC), according to updated results of the phase IIb LUX-Lung 7 study. [ESMO 2016, abstract LBA43]
Nivolumab did not meet the primary endpoint of superior progression-free survival (PFS) vs platinum-based chemotherapy in the phase III Checkmate026 trial in patients with stage IV recurrent, PD-L1–positive non-small-cell lung carcinoma (NSCLC), according to results reported recently at the European Society of Medical Oncology (ESMO) Congress 2016.
Intensive follow-up increased the detection of surgically treatable recurrent colorectal cancer (CRC), according to a study presented at the European Society for Medical Oncology (ESMO) Congress 2016 held in Copenhagen, Denmark. However, there appeared to be no advantage in combining computed tomography (CT) imaging and carcinoembryonic antigen (CEA) measurements in follow-up.
Data from trials presented at the European Society for Medical Oncology (ESMO) Congress 2016 showed clinically significant overall survival (OS) benefit with CTLA-4 and PD-1 inhibitors in patients with advanced melanoma.
The PD-L1 inhibitor atezolizumab significantly improved overall survival (OS) in patients with previously-treated advanced non-small cell lung cancer (NSCLC), compared with standard chemotherapy with docetaxel, according to the OAK* study presented at the recent European Society for Medical Oncology (ESMO) Congress 2016 in Copenhagen, Denmark.
Results of a recent clinical trial showed that treatment with niraparib, a poly ADP ribose polymerase (PARP) inhibitor, improved progression-free survival (PFS) by more than 15 months in patients with recurrent ovarian cancer responding to platinum.
Ipilimumab, given as adjuvant therapy after complete resection of stage III melanoma, significantly improved overall survival (OS) and distant metastases-free survival (DMFS) vs placebo, according to new results from the EORTC 18071 trial. [ESMO 2016, abstract LBA2_PR]
New data from the CheckMate 141 trial show that patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who receive nivolumab have better quality of life (QoL) than those treated with chemotherapy. [ESMO 2016, LBA4_PR; N Engl J Med 2016, doi: 10.1056/NEJMoa1602252]